Document Detail

Management of late anemia in Rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study).
MedLine Citation:
PMID:  8726237     Owner:  NLM     Status:  MEDLINE    
The management of (Rhesus) hemolytic disease of the fetus and newborn includes intrauterine transfusions to prevent the development of hydrops, treatment of the possible hyperbilirubinemia in the immediate postnatal period, and treatment of late anemia. Low levels of serum erythropoietin due to suppression of the bone marrow by multiple intrauterine transfusions is a suggested mechanism for this anemia. The aim of our study was to test whether recombinant human erythropoietin reduced the need for erythrocyte transfusions in these infants. Twenty infants with Rhesus isoimmunization were blindly randomized to treatment and control groups at the 2nd wk of life. The number of intrauterine and exchange transfusions and demographic data were similar in both groups. The infants in the treatment group received recombinant human erythropoietin, s.c. 200 U/kg of body weight three times a week for a period of 6 wk, whereas the infants in the control group received a placebo for the same period. In the treatment group, the mean number of erythrocyte transfusions was significantly lower than that of the control group (1.8 versus 4.2). The reticulocyte counts and Hb levels rose earlier in the treatment group. The platelet and neutrophil counts were similar in both groups throughout the study. This study demonstrates that recombinant human erythropoietin treatment decreases the need for erythrocyte transfusions in the late anemia of infants with Rh isoimmunization. Considering the risks of blood transfusions, this decrease in the donor exposure is worthwhile.
F Ovali; N Samanci; T Dağoğlu
Related Documents :
3505617 - Sudden death following white cell transfusion in a premature infant.
11196277 - Treatment of hemolytic disease of the newborn caused by anti-kell antibody with recombi...
15104657 - Platelet transfusion in an infant leading to formation of anti-d: implications for immu...
21218117 - Early assessment of the severity of asphyxia in term newborns using parameters of blood...
6628777 - Assessing cohort birth expectations data from the current population survey, 1971-1981.
24053167 - 'being in a womb' or 'playing musical chairs': the impact of place and space on infant ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Pediatric research     Volume:  39     ISSN:  0031-3998     ISO Abbreviation:  Pediatr. Res.     Publication Date:  1996 May 
Date Detail:
Created Date:  1996-10-21     Completed Date:  1996-10-21     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0100714     Medline TA:  Pediatr Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  831-4     Citation Subset:  IM    
Department of Obstetrics and Gynecology, Istanbul University, Istanbul Medical Faculty, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Hemolytic / blood,  drug therapy,  therapy
Blood Transfusion, Intrauterine
Double-Blind Method
Erythroblastosis, Fetal / blood,  drug therapy*,  therapy
Erythropoietin / therapeutic use*
Exchange Transfusion, Whole Blood
Hemoglobins / metabolism
Hydrops Fetalis / prevention & control
Infant, Newborn
Leukocyte Count
Platelet Count
Recombinant Proteins / therapeutic use
Reticulocyte Count
Reg. No./Substance:
0/Hemoglobins; 0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Decreased thrombin activity of fibrin clots prepared in cord plasma compared with adult plasma.
Next Document:  Granulocyte functions in children with cancer are differentially sensitive to the toxic effect of ch...